Logo of Clarity Pharmaceuticals (ASX:CU6)Latest Clarity Pharmaceuticals (ASX:CU6) News

Page 2
Page 2 of 5

Clarity Pharmaceuticals Advances Prostate Cancer Radiopharmaceuticals with $178m Cash and US Manufacturing Deal

Clarity Pharmaceuticals bolsters its commercial readiness with a $178.3 million cash reserve and a key US manufacturing agreement, while clinical trials for its prostate cancer imaging and therapeutic agents progress with promising data.
Ada Torres
31 July 2026

Healthcare Wrap - Week 27 (29 June -> 3 July) 2026

Cann Group, OncoSil and Imugene led a busy healthcare week as investors chased FDA steps, cancer trial news and balance-sheet fixes. Elsewhere, revenue growth, hospital contracts and fresh funding kept money flowing into names with near-term commercial milestones.
Logan Eniac
4 July 2026

Clarity Pharmaceuticals Showcases Superior Prostate Cancer Imaging and Therapy Data at EANM 2026

Clarity Pharmaceuticals will present compelling data at EANM 2026 demonstrating its 64Cu-SAR-bisPSMA imaging agent’s superior detection of prostate cancer recurrence and promising therapeutic results from 67Cu-SAR-bisPSMA in advanced disease.
Ada Torres
29 June 2026

Market Wrap - Week 18 (27 Apr -> 1 May) 2026

Small caps drove the biggest moves, with Alvo Minerals surging, Klevo extending a payments-fuelled rally, and FBR jumping on fresh contract news. At the larger end, takeover bids, mine funding deals and a strong Liontown update kept resources and corporate activity at the centre of trading.
Logan Eniac
2 May 2026

Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026

Biotech price swings were led by Dimerix’s slide, while TrivarX and LTR Pharma surged on clinical and commercial progress. Capital raisings, FDA milestones and first sales kept healthcare investors busy, but several early jumps faded as traders locked in gains.
Logan Eniac
2 May 2026

Clarity’s Cu-SAR-bisPSMA Doubles Lesion Detection, Advances Toward US Launch

Clarity Pharmaceuticals’ Phase II Co-PSMA trial confirms its Cu-SAR-bisPSMA PET imaging detects more than twice the prostate cancer lesions versus standard care, driving patient management changes. Phase III AMPLIFY recruitment closes, manufacturing deals inked, and cash sits near $198 million.
Ada Torres
30 Apr 2026

Healthcare Wrap - Week 16 (13 Apr -> 17 Apr) 2026

Big gains came from contracts, approvals and takeover interest, while several capital raisings and debt deals drew a cooler response. Diagnostics, radiopharma and medtech led the week, with buyers rewarding companies that showed clear sales, supply or hospital access.
Logan Eniac
18 Apr 2026

Clarity Expands US Manufacturing Capacity for Prostate Cancer Imaging Agent

Clarity Pharmaceuticals has secured a major manufacturing deal with Nucleus RadioPharma to produce its next-generation prostate cancer imaging agent, 64Cu-SAR-bisPSMA, ramping up supply ahead of anticipated US market entry.
Ada Torres
14 Apr 2026

Market Wrap - Week 13 (23 Mar -> 27 Mar) 2026

Micro-caps stole the spotlight, led by a boardroom reset at Killi and a blockbuster cancer update from Amplia. Energy explorers and a few big raisings moved the other way, as traders sold hard into fresh dilution and weak price action.
Logan Eniac
28 Mar 2026

Healthcare Wrap - Week 13 (23 Mar -> 27 Mar) 2026

Cancer drug data and two separate Mayo Clinic-linked deals drove the biggest moves this week. Investors paid up for clearer routes to hospital rollouts, while one digital screening name fell hard after early gains evaporated.
Logan Eniac
28 Mar 2026

Clarity Pharmaceuticals Secures Major Copper-64 Supply Deal with Theragenics

Clarity Pharmaceuticals has signed a significant manufacturing supply agreement with Theragenics to produce copper-64, a key isotope for its upcoming prostate cancer diagnostic, Cu-SAR-bisPSMA. This deal strengthens Clarity’s US supply network ahead of anticipated FDA approval and commercial launch.
Ada Torres
25 Mar 2026

Market Wrap - Week 12 (16 Mar -> 20 Mar) 2026

A brutal split opened up in small caps: a few stocks surged on hard approvals and funding, while many resource names slid even after announcing big numbers. The week’s tape looked simple: investors paid for certainty and sold anything that still needs time, permits, or more cash.
Logan Eniac
21 Mar 2026